Advances in vascular cognitive impairment 2006

Stroke

Volumn 38, Issue 2, 2007, Pages 241-244

  Bowler, John V ^a,c   Gorelick, Philip B ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ILLINOIS   (United States)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Vascular cognitive impairment

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; GLIBENCLAMIDE; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PHOSPHOLIPASE A2; ROSIGLITAZONE;

ALZHEIMER DISEASE; ATTRIBUTABLE RISK; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHROMOSOME 4; COGNITION; COGNITIVE DEFECT; DIABETES CONTROL; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SYNTHESIS; ISCHEMIC HEART DISEASE; LEUKOARAIOSIS; LIFESTYLE; METABOLIC SYNDROME X; MONOTHERAPY; NEUROPSYCHOLOGICAL TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; STROKE; WHITE MATTER;

EID: 33846603732     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000254712.39076.d6     Document Type: Review

References (32)

1. Bowler JV, Hachinski V. Current criteria for vascular dementia - a critical appraisal. In: Bowler JV, Hachinski V, eds. Vascular Cognitive Impairment. Preventable Dementia. Oxford, UK:Oxford University Press; 2003;1-11.
2. Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis D, Black SE, Powers WJ, DeCarli C, Merino JG, Kalaria RN, Vinters HV, Holtzman DM, Rosenberg GA, Dichgans M, Marler JR, Leblanc GG. National Institute of Neurological Disorders and Stroke - Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards. Stroke. 2006;37:2220-2241.
3. Gorelick PB. William Feinberg Lecture: cognitive vitality and the role of stroke and cardiovascular disease risk factors. Stroke. 2005;36:875-879.
4. Peilia R, White LR, Masaki K, Petrovitch H, Launer LJ. Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke. 2006;37:1165-1170.
5. Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, Tschanz JT, Mayer LS, Welsh-Bohmer KA, Breitner JC. Antihypertensive medication use and incident Alzheimer disease. Arch Neurol. 2006;63:686-692.
6. Shah RC, Wilson RS, Bienas JL, Arvanitakis Z, Evans DA, Bennett DA. Relation of blood pressure to risk of incident Alzheimer's disease and change in global cognitive function in older persons. Neuroepidemiology. 2006;26:30-36.
7. Feigin V, Ratnasabapathy Y, Anderson C. Does blood pressure lowering treatment prevent dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease. J Neurol Sci. 2005;229-230:151-155.
8. McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database of Systematic Reviews. 2006; Issue 2. Art. No.: CD004034. DOI: 10.1002/14651858.CD004034. pub2.
9. Strachan MWJ. Insulin and cognitive function. The Lancet. 2003;362:1253.
10. Craft S. Insulin resistance and cognitive impairment:a view through the prism of epidemiology. Arch Neurol. 2005;62:1043-1044.
11. Geroldi C, Frisoni GB, Paolisso G, Bandinelli S, Lamponi M, Abbactecola M, Zanetti O, Guralnik JM, Ferrucci L. Insulin resistance in cognitive impairment. The InCHIANTI Study. Arch Neurol. 2005;62:1067-1072.
12. Emanuele E, D'Angelo A, Tomaino C, Binetti G, Ghidoni R, Politi P, Bernardi L, Maletta R, Bruni AC, Geroldi D. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol. 2005;62:1734-1736.
13. Ryan CM, Freed MI, Rood JA, Cobitz AR, Waterhouse BR, Strachan MWJ. Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care. 2006;29:345-351.
14. Jacobson AM. Cognitive function not impaired by tight glucose control. Diabetic Microvascular Complications Today July/August 2006;1:28 (presented by Jacobson AM, et al at the American Diabetes Association 66th Scientific Sessions, June 9-13, 2006, Washington, DC).
15. Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, Tylavsky FA, Newman AB. The metabolic syndrome, inflammation, and risk or cognitive decline. JAMA. 2004;292:2237-2242.
16. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer L. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol. 2002;52:168-174.
17. Weaver JD, Huang M-H, Albert M, Harris T, Rowe JW, Seeman TE. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Ann Neurol. 2002;59:571-578.
18. van Oijen M, van der Meer IM, Hofman A, Witteman JCM, Koudstaal PJ, Breteler MM. Lipoprotein-associated phospholipase A2 is associated with risk of dementia. Ann Neurol. 2006;59:139-144.
19. Kwon HM, Kim BJ, Lee S-H, Choi SH, O BH, Yoon BW. Metabolic syndrome as an independent risk factor of silent brain infarction in healthy people. Stroke. 2006;37:466-470.
20. Carmelli D, DeCarli C, Swan GE, Jack LM, Reed T, Wolf PA, Miller BL. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke. 1998;29:1177-1181.
21. Atwood LD, Wolf PA, Heard-Costa NL, Massaro JM, Beiser A, D'Agostino RB, DeCarli C. Genetic variation in white matter hyperintensity volume in the Framingham Study. Stroke. 2004;35:1609-1613.
22. Turner ST, Jack CR, Fornage M, Mosley TH, Boerwinkle E, de Andrade M. Heritability of leukoaraiosis in hypertensive sibships. Hypertension. 2004;43:483-487.
23. DeStefano AL, Atwood LD, Massaro JM, Heard-Costa N, Beiser A, Au R, Wolf PA, DeCarli C. Genome-wide scan for white matter hyperintensity: The Framingham Heart Study. Stroke. 2006;37:77-81.
24. Gould DB, Phalan FC, van Mil SE, Sundberg JP, Vahedi K, Massin P, Bousser MG, Heutink P, Miner JH, Tournier-Lasserve E, John SWM. Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N Engl J Med. 2006;354:1489-1496.
25. Fernando MS, Simpson JE, Matthews F, Brayne C, Lewis CE, Barber R, Kalaria RN, Forster G, Esteves F, Wharton SB, Shaw PJ, O'Brien JT, Ince PG; on behalf of the MRC Cognitive Function and Ageing Neuropathology Study Group. White matter lesions in an unselected cohort of the elderly: molecular pathology suggests origin from chronic hypoperfusion injury: * Annex - Supplemental Online-Only Content. Stroke. 2006;37:1391-1398.
26. Henskens LHG, Kroon AA, van Boxtel MPJ, Hofman PAM, de Leeuw PW. Associations of the angiotensin II type 1 receptor A1166C and the endothelial NO synthase G894T gene polymorphisms with silent subcortical white matter lesions in essential hypertension. Stroke. 2005;36:1869-1873.
27. Au R, Massaro JM, Wolf PA, Young ME, Beiser A, Seshadri S, D'Agostino RB, DeCarli C. Association of white matter hyperintensity volume with decreased cognitive functioning: The Framingham Heart Study. Arch Neurol. 2006;63:246-250.
28. Longstreth WT Jr, Arnold AM, Beauchamp NJ Jr, Manolio TA, Lefkowitz D, Jungreis C, Hirsch CH, O'Leary DH, Furberg CD. Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: The Cardiovascular Health Study. Stroke. 2005;36:56-61.
29. Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Jolles J, Koudstaal PJ, Hofman A, Breteler MMB. Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain. 2005;128:2034-2041.
30. Schmidt R, Ropele S, Enzinger C, Petrovic K, Smith S, Schmidt H, Matthews PM, Fazekas F. White matter lesion progression, brain atrophy, and cognitive decline: the Austrian Stroke Prevention study. Ann Neurol. 2005;58:610-616.
31. van den Heuvel DMJ, ten Dam VH, de Craen AJM, dmiraal-Behloul F, Olofsen H, Bollen ELEM, Jolles J, Murray HM, Blauw GJ, Westendorp RGJ, van Buchem MA. Increase in periventricular white matter hyperintensities parallels decline in mental processing speed in a non-demented elderly population. J Neurol Neurosurg Psychiatry. 2006;77:149-153.
32. Garde E, Lykke Mortensen E, Rostrup E, Paulson OB. Decline in intelligence is associated with progression in white matter hyperintensity volume. J Neurol Neurosurg Psychiatry. 2005;76:1289-1291.